A novel inhibitory mechanism of nitrogen-containing bisphosphonate on the activity of Cl- extrusion in osteoclasts

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 7, 2013, Pages 589-598

  Ohgi, Kimiko ^a   Kajiya, Hiroshi ^a   Okamoto, Fujio ^a   Nagaoka, Yoshiyuki ^a   Onitsuka, Tokuya ^a   Nagai, Atsushi ^a   Sakagami, Ryuji ^a   Okabe, Koji ^a  

^a FUKUOKA DENTAL COLLEGE   (Japan)

Author keywords

Bisphosphonates; Chloride current; Farnesyl diphosphate synthase; Osteoclasts; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CHLORIDE; ETIDRONIC ACID; GERANYLTRANSFERASE; NITROGEN CONTAINING BISPHOSPHONATE DERIVATIVE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ACIDIFICATION; ANIMAL CELL; ARTICLE; BONE MARROW CELL; CHLORIDE CURRENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME INHIBITION; EXTRACELLULAR SPACE; MACROPHAGE; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS;

ALKYL AND ARYL TRANSFERASES; ANIMALS; BONE MARROW CELLS; CELL LINE; CELLS, CULTURED; CHLORIDES; DIPHOSPHONATES; DITERPENES; GENE SILENCING; GERANYLTRANSTRANSFERASE; MALE; MICE; NITROGEN; OSTEOCLASTS; RNA, SMALL INTERFERING;

EID: 84879068590     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-013-0857-0     Document Type: Article

References (47)

1. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH (1992) Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33:1657-1663
2. Amin D, Cornell SA, Perrone MH, Bilder GE (1996) 1-Hydroxy-3- (methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Arzneimittelforschung 46:759-762
3. Auzanneau C, Thoreau V, Kitzis A, Becq F (2003) A novel voltage-dependent chloride current activated by extracellular acidic pH in cultured rat Sertoli cells. J Biol Chem 278:19230-19236
4. Bénichou O, Cleiren E, Gram J, Bollerslev J, de Vernejoul MC, Van Hul W (2001) Mapping of autosomal dominant osteopetrosis type II (Albers-Schönberg disease) to chromosome 16p13.3. Am J Hum Genet 69:647-654
5. Blair HC, Teitelbaum SL, Ghiselli R, Gluck S (1989) Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 245:855-857
6. Caraglia M, Budillon A, Tagliaferri P, Marra M, Abbruzzese A, Caponigro F (2005) Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. Curr Drug Targets 6:301-323
7. Casey PJ (1995) Mechanisms of protein prenylation and role in G protein function. Biochem Soc Trans 23:161-166
8. + exchanger CLC-7. J Physiol 590:3421-3430
9. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ (2000) Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15:1467-1476
10. Davignon J (2000) Beneficial cardiovascular pleiotropic effects of statins. Circulation 109:1139-1143
11. Delmas PD, Meunier PJ (1997) The management of Paget's disease of bone. N Engl J Med 336:558-566
12. Diewald L, Rupp J, Dreger M, Hucho F, Gillen C, Nawrath H (2002) Activation by acidic pH of CLC-7 expressed in oocytes from Xenopus laevis. Biochem Biophys Res Commun 291:421-424
13. Dobrucali A, Tobey NA, Awayda MS, Argote C, Abdulnour-Nakhoul S, Shao W, Orlando RC (2002) Physiological and morphological effects of alendronate on rabbit esophageal epithelium. Am J Physiol Gastrointest Liver Physiol 283:G576-G586
14. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235-242
15. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96:133-138
16. Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19:80-100
17. Forgac M (1989) Structure and function of vacuolar class of ATP-driven proton pumps. Physiol Rev 69:765-796
18. Gibbs JB, Oliff A, Kohl NE (1994) Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77:175-178
19. Hasmim M, Bieler G, Rüegg C (2007) Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost 5:166-173
20. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478-1487
21. Jilka RL, Takahashi K, Munshi M, Williams DC, Roberson PK, Manolagas SC (1998) Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J Clin Invest 101:1942-1950
22. - channels and their inhibition in mutant (G215R) associated with autosomal dominant osteopetrosis type II in native osteoclasts and hClcn7 gene-expressing cells. Pflugers Arch 458:1049-1059
23. Karsdal MA, Henriksen K, Sørensen MG, Gram J, Schaller S, Dziegiel MH, Heegaard AM, Christophersen P, Martin TJ, Christiansen C, Bollerslev J (2005) Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 166:467-476
24. Kelly ME, Dixon SJ, Sims SM (1994) Outwardly rectifying chloride current in rabbit osteoclasts is activated by hyposmotic stimulation. J Physiol 475:377-389
25. Kornak U, Kasper D, Bösl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G, Jentsch TJ (2001) Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104:205-215
26. +-exchanger and requires Ostm1 for transport activity. EMBO J 30:2140-2152
27. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443
28. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ (1998a) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581-589
29. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ (1998b) Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 13:1668-1678
30. Monier-Faugere MC, Geng Z, Paschalis EP, Qi Q, Arnala I, Bauss F, Boskey AL, Malluche HH (1999) Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res 14:1768-1778
31. Nobles M, Higgins CF, Sardini A (2004) Extracellular acidification elicits a chloride current that shares characteristics with ICl(swell). Am J Physiol Cell Physiol 287:C1426-C1435
32. - currents and bone resorption activity in mouse osteoclasts. Naunyn Schmiedebergs Arch Pharmacol 383:79-90
33. Okamoto F, Kajiya H, Fukushima H, Jimi E, Okabe K (2004) Prostaglandin E2 activates outwardly rectifying Cl(-) channels via a cAMP-dependent pathway and reduces cell motility in rat osteoclasts. Am J Physiol Cell Physiol 287:C114-C124
34. Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF (1996) A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 11:150-159
35. Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9:2643-2658
36. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(12 Suppl):2961-2978
37. Russell RG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25:97-106
38. Sabirov RZ, Prenen J, Droogmans G, Nilius B (2000) Extra- and intracellular proton-binding sites of volume-regulated anion channels. J Membr Biol 177:13-22
39. Schaller S, Henriksen K, Sveigaard C, Heegaard AM, Hélix N, Stahlhut M, Ovejero MC, Johansen JV, Solberg H, Andersen TL, Hougaard D, Berryman M, Shiødt CB, Sørensen BH, Lichtenberg J, Christophersen P, Foged NT, Delaissé JM, Engsig MT, Karsdal MA (2004) The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 19:1144-1153
40. Seabra MC, James GL (1998) Prenylation assays for small GTPases. Methods Mol Biol 84:251-260
41. Shao W, Orlando RC, Awayda MS (2005) Bisphosphonates stimulate an endogenous nonselective cation channel in Xenopus oocytes: potential mechanism of action. Am J Physiol Cell Physiol 289:248-256
42. Shen BQ, Widdicombe JH, Mrsny RJ (1995) Effects of lovastatin on trafficking of cystic fibrosis transmembrane conductance regulator in human tracheal epithelium. J Biol Chem 270:25102-25106
43. Shi CY, Wang R, Liu CX, Jiang H, Ma ZY, Li L, Zhang W (2009) Simvastatin inhibits acidic extracellular pH-activated, outward rectifying chloride currents in RAW264.7 monocytic-macrophage and human peripheral monocytes. Int Immunol 9:247-252
44. van Beek E, Löwik C, van der Pluijm G, Papapoulos S (1999a) The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 14:722-729
45. van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S (1999b) Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 255:491-494
46. Yamamoto S, Ehara T (2006) Acidic extracellular pH-activated outwardly rectifying chloride current in mammalian cardiac myocytes. Am J Physiol Heart Circ Physiol 290:H1905-H1914
47. Zhang FL, Casey PJ (1996) Influence of metal ions on substrate binding and catalytic activity of mammalian protein geranylgeranyltransferase type-I. Biochem J 320:925-932 Technology Technology